Stay updated on Pembrolizumab in Triple Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check25 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1.0%
- Check53 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check68 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed information about a clinical trial for Pembrolizumab in treating metastatic triple negative breast cancer, while adding new identifiers and collaborators related to the study.SummaryDifference57%
Stay in the know with updates to Pembrolizumab in Triple Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.